2020 Surgery Grand Rounds | CAR T Malignant Brain Tumors: Progress, Promises and Challenges

Duarte, CA US
November 12, 2020

Glioblastomas (GBM) are a challenging malignancy with few good treatment options. Current treatment involves surgery, radiation, and chemotherapy. The prognosis remains poor despite multimodality therapy and the field is actively exploring additional options in its treatment.

The management of this disease is highly specialized and the pursuit of investigational therapies is essential for the advancement in the treatment of this disease as it otherwise has poor prognosis. Few physicians have expertise in this field and the dissemination of this knowledge is important. Furthermore, the experiences of investigational therapies in this disease process have the possibility to be translated into other disease processes. 

Target Audience

Surgeons, medical oncologists, physicians, nurses, and all other health care professionals interested in this subject matter. 

Learning Objectives

  • Discuss the rationale for using CAR T cell immunotherapy for treatment of malignant gliomas.
  • Identify side effects of CAR T cell therapy for glioblastoma (GBM).
  • Outline potential barriers for effective CAR T cell therapy for GBM.
  • Distinguish CAR T cell delivery methods into the central nervous system (CNS). 

Additional Information

AttachmentSize
AB 1195 Bibliography188.36 KB
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2020 Surgery Grand Rounds | CAR T Malignant Brain Tumors: Progress, Promises and Challenges for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Activity opens: 
11/12/2020
Activity expires: 
11/13/2020
Event starts: 
11/12/2020 - 7:00am
Event ends: 
11/12/2020 - 8:00am
City of Hope
1500 E Duarte Rd
Duarte, CA 91010
United States

Virtual Meeting- Zoom

Behnam Badie, MD, FACS  Chief, Division of Neurosurgery; Heritage Provider Network Professor in Gene Therapy; Director, Brain Tumor Program; City of Hope

Dr. Badie has indicated that he receives Grant/Research Support from Mustang, and has Other financial/material interest in Mustang.

 

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

 AMA PRA Category 1™  1.0

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this 2020 Surgery Grand Rounds | CAR T Malignant Brain Tumors: Progress, Promises and Challenges for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
Please login or register to take this activity.